Irbesartan

A spiro compound, biphenyl and tetrazole derivative that acts as an angiotensin II type 1 receptor antagonist. It is used in the management of HYPERTENSION, and in the treatment of kidney disease.

Also Known As:

2-N-Butyl-3-((2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl)-1,3-diazaspiro(4,4)non-1-en-4-one; Aprovel; Avapro; BMS 186295; BMS-186295; Karvea; SR 47436; SR-47436; SR47436; 1,3-Diazaspiro(4.4)non-1-en-4-one, 2-butyl-3-((2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl)-

Networked: 907 relevant articles (141 outcomes, 375 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Carson, Peter E: 27 articles (08/2021 - 02/2008)
2.	Komajda, Michel: 27 articles (08/2021 - 10/2005)
3.	Zile, Michael R: 26 articles (08/2021 - 02/2008)
4.	Anand, Inder S: 24 articles (08/2021 - 03/2010)
5.	Parving, Hans-Henrik: 22 articles (01/2016 - 06/2002)
6.	McKelvie, Robert S: 21 articles (08/2021 - 02/2010)
7.	McMurray, John J V: 19 articles (08/2021 - 02/2008)
8.	Kahan, Thomas: 17 articles (12/2013 - 04/2002)
9.	Pfeffer, Marc A: 16 articles (08/2021 - 04/2003)
10.	Malmqvist, Karin: 15 articles (12/2013 - 04/2002)

Related Diseases

1.	Hypertension (High Blood Pressure) 01/01/2008 - "* Furthermore, the proportion of patients with severe hypertension achieving controlled BP of < 140/90 mmHg was significantly greater at all timepoints of the trial compared with irbesartan monotherapy. " 09/01/2019 - "Moreover, compared with control group, ALDH2 over expression significantly improved irbesartan treatment, verified by hypertension related index. " 07/01/2004 - "In conclusion, treatment of hypertension with irbesartan resulted in a significant reduction in the voltage criteria for LVH, although an effect on LVM was only seen in subjects with high baseline LVM. " 05/01/1999 - "Irbesartan is effective in the elderly and non-elderly, men and women and in cases of mild and severe hypertension. " 09/01/2019 - "Rats with Hypertension indeed benefited from irbesartan treatment. "
2.	Diabetic Nephropathies (Diabetic Nephropathy) 09/01/2021 - "It was the first time to study the pharmacokinetics of DDI between BBR and irbesartan successfully, which would be necessary and beneficial to explore the clinical safety and efficacy of the combination of BBR and irbesartan in the treatment of diabetic nephropathy." 03/01/2010 - "Irbesartan was more effective in preventing deterioration of kidney function in patients with diabetic nephropathy, being cost effective from a German perspective. " 08/01/2009 - "In addition, irbesartan has been shown to be effective in both early and late stage diabetic nephropathy. " 01/01/2016 - "Corrigendum to "Irbesartan Ameliorates Diabetic Nephropathy by Suppressing the RANKL-RANK-NF-κB Pathway in Type 2 Diabetic db/db Mice"." 01/01/2016 - "Irbesartan Ameliorates Diabetic Nephropathy by Suppressing the RANKL-RANK-NF-κB Pathway in Type 2 Diabetic db/db Mice."
3.	Type 2 Diabetes Mellitus (MODY) 06/01/2007 - "Irbesartan was projected to improved life expectancy and reduce costs compared to placebo in the Hungarian setting in hypertensive patients with type 2 diabetes and microalbuminuria." 11/01/2006 - "In France, early irbesartan treatment improved quality and length of life and reduced costs in hypertensive patients with type 2 diabetes and microalbuminuria. " 12/01/1997 - "Irbesartan lowers blood pressure and ameliorates renal injury in experimental non-insulin-dependent diabetes mellitus." 03/01/2015 - "Our study suggests that irbesartan could ameliorate cardiac remodeling and dysfunction in type 2 diabetes, and these beneficial effects were associated with its ability to suppress the activation of PKD and ER stress. " 09/01/2011 - "In a post hoc analysis of the Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria (IRMA)-2 trial we first assessed the individual variability in UAE and SBP response (0-6 months) in 531 subjects. "
4.	Proteinuria 04/01/2014 - "Irbesartan somewhat lowered blood pressure and reduced proteinuria, tubulointerstitial cell proliferation and glomerulosclerosis. " 06/01/2012 - "This rate of decline was slower with longer duration of irbesartan treatment and only partly explained by observed reductions in BP and proteinuria." 06/01/2012 - "Irbesartan produced rapid and sustained proteinuria reductions, which only partially mediated treatment response. " 06/01/2012 - "Irbesartan slowed the rate of ΔeGFR decline irrespective of baseline CKD stage, BP or proteinuria level. " 12/01/2011 - "High-dose irbesartan can effectively lower the mild and moderate proteinuria in CKD patients with a good safety and tolerance and the efficacy is independent of lowering blood pressure."
5.	Heart Failure 10/01/2005 - "The Irbesartan in Heart Failure with Preserved Systolic Function (I-PRESERVE) is enrolling 4100 subjects with HF-PSF to evaluate whether 300 mg irbesartan is superior to placebo in reducing mortality and prespecified categories of cardiovascular hospitalizations. " 12/01/1997 - "Preliminary studies evaluating the efficacy of irbesartan in patients with heart failure have produced encouraging results. " 08/01/2021 - "Models were derived in 4116 patients in the Irbesartan in Heart Failure with Preserved Ejection Fraction trial (I-Preserve), using competing risks regression analysis. " 02/21/2017 - "Clinical and Echocardiographic Characteristics and Cardiovascular Outcomes According to Diabetes Status in Patients With Heart Failure and Preserved Ejection Fraction: A Report From the I-Preserve Trial (Irbesartan in Heart Failure With Preserved Ejection Fraction)." 01/01/2017 - "Baseline IGFBP7 (BL-IGFBP7; n = 302) and 6-month change (Δ; n = 293) were evaluated in the Irbesartan in Heart Failure and Preserved Ejection Fraction (I-PRESERVE) trial. "

Related Drugs and Biologics

1.	Angiotensin Receptor Antagonists
2.	Losartan (Cozaar)
3.	Antihypertensive Agents (Antihypertensives)
4.	Hydrochlorothiazide (Esidrix)
5.	Amlodipine (Norvasc)
6.	candesartan
7.	Telmisartan (Micardis)
8.	Angiotensin II
9.	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)
10.	Enalapril

Related Therapies and Procedures

1.	Therapeutics
2.	Electric Countershock (Cardioversion)
3.	Mechanical Ventilators (Ventilator)
4.	Emergency Treatment
5.	Nephrectomy